8 facts about kandesartan Review article
Article Sidebar
Main Article Content
Abstract
Actual guidelines of the Polish Society of Hypertension on the management of patients with hypertension suggest 5 main groups of drugs used in the treatment of hypertension: angiotensin-converting enzyme inhibitors, calcium channel antagonists, angiotensin II receptor blockers, diuretics and β-blockers. Each of these groups has interesting substances that despite the same mechanism of action present certain additional properties. Candesartan, a representative group of antagonists of angiotensin II receptors have been shown to reduce morbidity and mortality in patients with heart failure, effectively lower blood pressure, reduce the risk of stroke in patients with isolated systolic hypertension, and possibly reduce the risk of development of diabetes. At the same time, it is very well tolerated drug. Candesartan with its efficacy and good tolerance of the treatment is a good alternative for the treatment of a wide range of patients with hypertension.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze 2015.
3. Mendis B., Page S.R.: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin. Pharmacother. 2009; 10(12): 1995-2007.
4. Cernes R., Mashavi M., Zimlichman R.: Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc. Health Risk Manag. 2011; 7: 749-759.
5. McMurray J.J., Ostergren J., Swedberg K. et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362(9386): 767-771.
6. Eguchi K., Kario K., Shimada K.: Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am. J. Cardiol. 2003; 92(5): 621-624.
7. Malmqvist K., Kahan T., Dahl M.: Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am. J. Hypertens. 2000; 13(5 Pt 1): 504-511.
8. Papademetriou V., Farsang C., Elmfeldt D. et al.: Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol. 2004; 44(6): 1175-1180.
9. McInnes G.T., O’Kane K.P., Jonker J., Roth J.: The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J. Hum. Hypertens. 1997; 11 Suppl. 2: S75-S80.
10. Cuspidi C., Muiesan M.L., Valagussa L. et al.: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens. 2002; 20(11): 2293-2300.
11. Barrios V., Escobar C., Calderon A. et al.: Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J. Renin Angiotensin Aldosterone Syst. 2006; 7(4): 236-242.
12. Shimizu M., Hoshide S., Ishikawa J. et al.: Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. Am. J. Hypertens. 2015; 28(8): 980-986.